Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 9, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of the company's common stock.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 17, 2024.
- Edgemond exercised options to acquire a total of 8,332 shares at exercise prices of $120.26 and $117.76.
- Simultaneously, he sold a total of 4,802 shares at a price of $345.41 per share.
- After these transactions, Edgemond directly owns 3,740 shares of common stock and holds options for 145,500 shares at $117.76 and 32,672 shares at $120.26.
- The transactions also included 'sell-to-cover' exercises where some shares were sold to cover the cost of exercising the options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Executive stock sales are a common occurrence, and the use of a 10b5-1 plan indicates that these sales were pre-planned and not based on any inside information. Investors often monitor these transactions for insights into management's perspective on the company's value.
Comparison to Industry Standards
- Executive compensation practices, including stock options, are common across the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation packages.
- The use of Rule 10b5-1 trading plans is a standard practice to avoid accusations of insider trading.
- The size and frequency of these transactions are typical for executives at publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| 03/15/2017 | Date stock options exercisable |
| 03/15/2021 | Date stock options exercisable |
| 05/17/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 09/04/2024 | Date of common stock acquired under Employee Stock Purchase Plan |
| 09/09/2024 | Date of stock option exercise and sale of shares |
| 09/10/2024 | Date of signature of the Form 4 filing |
| 03/15/2026 | Expiration date of stock options |
| 03/15/2027 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.